DESC:The following specification describes the invention.

INTRODUCTION
One aspect of the present application relate to amorphous solid dispersion and pharmaceutical compositions of Larotrectinib sulfate. Another aspect of the present application relate to processes for the preparation of amorphous solid dispersion of Larotrectinib sulfate.
Larotrectinib sulfate is the adopted name of drug compound manufactured by Loxo Oncology having a chemical name: (3S)-N-{5-[(2R)-2-(2,5-difluorophenyl)-1- pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl}-3-hydroxy-1-pyrrolidinecarboxamide sulfate and the structure as below.
H2SO4
Larotrectinib is an inhibitor of the tropomyosin receptor kinases (TRK) approved by US FDA as VITRAKVI®capsules and solution for Oral use to treat solid tumors in adult and pediatric patients.
US 8513263 B2 first discloses Larotrectinib, its hydrogen sulfate salt, preparative process, pharmaceutical composition and their use for treating disorders such as pain, cancer, inflammation, neurodegenerative disease and Typanosoma cruzi infection.
WO 2016077841 A1 discloses crystalline Form I-HS of Larotrectinib sulfate and its preparation. Further, it discloses that the earlier processes for the preparation of Larotrectinib and its sulfate salt (as disclosed in US 8513263 B2) produces amorphous Larotrectinib and amorphous Larotrectinib sulfate. However, WO 2016077841 A1 indicates that the amorphous form of Larotrectinib sulfate is unstable and hygroscopic in nature.
Amorphous solid dispersions of Larotrectinib sulfate disclosed in the instant application are useful to enhance stability of amorphous form and also to meet required biopharmaceutics.
SUMMARY
In one aspect, the present application provides an amorphous solid dispersion of Larotrectinib sulfate together with atleast one pharmaceutically acceptable excipient.

In another aspect, the present application provides a process for the preparation of an amorphous solid dispersion of Larotrectinib sulfate together with atleast one pharmaceutically acceptable excipient, comprising the steps of:
a) providing a solution of Larotrectnib sulfate and atleast one pharmaceutically acceptable excipient in a suitable solvent;
b) removing the solvent from the solution obtained in step a);
c) isolating the amorphous solid dispersion of Larotrectinib sulfate;
d) optionally, combining amorphous solid dispersion of step c) with atleast one additional pharmaceutically acceptable excipient.

In another aspect, the present application provides a pharmaceutical composition comprising an amorphous solid dispersion of Larotrectinib sulfate thereof together with atleast one pharmaceutically acceptable excipient.

BRIEF DESCRIPTION OF THE DRAWING
Figure 1 is an illustrative X-ray powder diffraction pattern of amorphous solid dispersion of Larotrectinib sulfate thereof with HPMCAS prepared by the method of Example 1.
Figure 2 is an illustrative X-ray powder diffraction pattern of amorphous solid dispersion of Larotrectinib sulfate thereof with HPMC-pthalate prepared by the method of Example 2.
Figure 3 is an illustrative X-ray powder diffraction pattern of amorphous solid dispersion of Larotrectinib sulfate thereof with HPMC prepared by the method of Example 3.
Figure 4 is an illustrative X-ray powder diffraction pattern of amorphous solid dispersion of Larotrectinib sulfate thereof with HPC prepared by the method of Example 4.
Figure 5 is an illustrative X-ray powder diffraction pattern of amorphous solid dispersion of Larotrectinib sulfate thereof with Povidone prepared by the method of Example 5.
Figure 6 is an illustrative X-ray powder diffraction pattern of amorphous solid dispersion of Larotrectinib sulfate thereof with Copovidone prepared by the method of Example 6.

DETAILED DESCRIPTION
In an aspect, the present application provides amorphous solid dispersion of Larotrectinib sulfate together with atleast one pharmaceutically acceptable excipient.
In embodiments, the present application provides an amorphous solid dispersion of Larotrectinib sulfate free from crystalline Larotrectinib sulfate. In embodiments, the present application provides an amorphous solid dispersion, wherein the content of crystalline Larotrectinib sulfate is below the limit of detection, as measured by a suitable technique such as X-ray diffraction or differential scanning calorimetry.
In embodiments, the amorphous solid dispersion of Larotrectinib sulfate is stable at all three ICH specified packing and storage conditions, for atleast one month or more. The solid dispersion is stable at 40° ± 2°C & 75% ± 5% RH; 25° ± 2°C 60% ± 5% RH and 2-8° C storage conditions for atleast 6 months or more; for atleast 3 months or more; for atleast one month or more.
In embodiments, the present application provides the amorphous solid dispersion of Larotrectinib sulfate together with atleast one pharmaceutically acceptable excipient having a glass transition temperature of about ambient temperatures of about 50°C or above.
In embodiments, the pharmaceutically acceptable excipient is a water soluble polymeric excipient. In embodiments, the pharmaceutically acceptable excipient may be selected from the group consisting of polyvinyl pyrrolidone, povidone K-30, povidone K-60, Povidone K-90, polyvinylpyrrolidone vinylacetate, co-povidone NF, polyvinylacetal diethylaminoacetate (AEA®), polyvinyl acetate phthalate, polysorbate 80, polyoxyethylene–polyoxypropylene copolymers (Poloxamer® 188), polyoxyethylene (40) stearate, polyethyene glycol monomethyl ether, polyethyene glycol, poloxamer 188, pluronic F-68, methylcellulose, methacrylic acid copolymer (Eudragit or Eudragit-RLPO), hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate (HPMC-AS), hydroxypropylmethyl cellulose, hydroxypropyl cellulose SSL(HPC-SSL), hydroxypropyl cellulose SL(HPC-SL), hydroxypropyl cellulose L (HPC-L), hydroxyethyl cellulose, Soluplus® (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (PCL-PVAc-PEG)), gelucire 44/14, ethyl cellulose, D-alpha-tocopheryl polyethylene glycol 1000 succinate, cellulose acetate phthalate, carboxymethylethylcelluloseand the like; cyclodextrins, gelatins, hypromellose phthalates, sugars, polyhydric alcohols, and the like; water soluble sugar excipients, preferably having low hygroscopicity, which include, but are not limited to, mannitol, lactose, fructose, sorbitol, xylitol, maltodextrin, dextrates, dextrins, lactitol and the like; polyethylene oxides, polyoxyethylene derivatives, polyvinyl alcohols, propylene glycol derivatives and the like; organic amines such as alkyl amines (primary, secondary, and tertiary), aromatic amines, alicyclic amines, cyclic amines, aralkyl amines, hydroxylamine or its derivatives, hydrazine or its derivatives, and guanidine or its derivatives, or any other excipient at any aspect of present application. The use of mixtures of more than one of the pharmaceutical excipients to provide desired release profiles or for the enhancement of stability is within the scope of this invention. Solid dispersions of the present application also include the solid dispersions of Larotrectinib sulfate together with a suitable non-polymeric excipient by employing techniques known in the art or procedures described or exemplified in any aspect of the instant application. In preferred embodiments, the pharmaceutically acceptable excipients may be selected from the group consisting of Povidone, co-povidone, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hyroxypropylmthyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate and hydroxyethyl cellulose.
In embodiments, the ratio of the Larotrectinib sulfate and the pharmaceutically acceptable excipient may range from about 1: 0.1 to 1: 2.

In another aspect, the present application provides amorphous solid dispersion of Larotrectinib sulfate together with alteast one pharmaceutical excipients selected from the group consisting of Povidone, co-povidone, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hyroxypropylmthyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate and hydroxyethyl cellulose.

In another aspect, the present application provides a process for the preparation of an amorphous solid dispersion of Larotrectinib sulfate, comprising the steps of:
a) providing a solution of Larotrectinib sulfate and atleast one pharmaceutically acceptable excipient in a suitable solvent;
b) removing the solvent from the solution obtained in step a);
c) isolating the amorphous solid dispersion of Larotrectinib sulfate;
d) optionally, combining amorphous solid dispersion of step c) with atleast one additional pharmaceutically acceptable excipient.

In an embodiment, suitable solvent at step a) of this aspect may be selected from C1-C6 alcohols, C3-C6 ketones, C5-C8 aliphatic or aromatic hydrocarbons, C3-C6 esters, C2-C6 aliphatic or cyclic ethers, C2-C6 nitriles, halogenated hydrocarbons, water or mixtures thereof.
In preferred embodiment, the suitable solvent may be selected from the group consisting of alcohol solvents such as methanol, ethanol, 2-propanol, 1-butanol, 2-butanol, 1-pentanol, 2-pentanol, 3-pentanol; dichloromethane, tetrahydrofuran; ketone solvents such as acetone, methyl ethyl ketone, methyl isobutyl ketone; esters solvents such as methyl acetate, ethyl acetate, isopropyl acetate; water and mixtures thereof.
In an embodiment, atleast one pharmaceutically acceptable excipient may be selected from the group consisting of polyvinyl pyrrolidone, povidone K-30, povidone K-60, Povidone K-90, polyvinylpyrrolidone vinylacetate, co-povidone NF, polyvinylacetal diethylaminoacetate (AEA®), polyvinyl acetate phthalate, polysorbate 80, polyoxyethylene–polyoxypropylene copolymers (Poloxamer® 188), polyoxyethylene (40) stearate, polyethyene glycol monomethyl ether, polyethyene glycol, poloxamer 188, pluronic F-68, methylcellulose, methacrylic acid copolymer (Eudragit or Eudragit-RLPO), hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate (HPMC-AS), hydroxypropylmethyl cellulose, hydroxypropyl cellulose SSL(HPC-SSL), hydroxypropyl cellulose SL(HPC-SL), hydroxypropyl cellulose L (HPC-L), hydroxyethyl cellulose, Soluplus® (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (PCL-PVAc-PEG)), gelucire 44/14, ethyl cellulose, D-alpha-tocopheryl polyethylene glycol 1000 succinate, cellulose acetate phthalate, carboxymethylethylcelluloseand the like; cyclodextrins, gelatins, hypromellose phthalates, sugars, polyhydric alcohols, and the like; water soluble sugar excipients, preferably having low hygroscopicity, which include, but are not limited to, mannitol, lactose, fructose, sorbitol, xylitol, maltodextrin, dextrates, dextrins, lactitol and the like; polyethylene oxides, polyoxyethylene derivatives, polyvinyl alcohols, propylene glycol derivatives and the like; organic amines such as alkyl amines (primary, secondary, and tertiary), aromatic amines, alicyclic amines, cyclic amines, aralkyl amines, hydroxylamine or its derivatives, hydrazine or its derivatives, and guanidine or its derivatives, or any other excipient at any aspect of present application. The use of mixtures of more than one of the pharmaceutical excipients to provide desired release profiles or for the enhancement of stability is within the scope of this invention. Also, all viscosity grades, molecular weights, commercially available products, their copolymers, and mixtures are all within the scope of this invention without limitation. Solid dispersions of the present application also include the solid dispersions obtained by combining Larotrectinib sulfate with a suitable non-polymeric excipient by employing techniques known in the art or procedures described or exemplified in any aspect of the instant application.
In an embodiment, providing a solution at step a) may be carried out by dissolving Larotrectinib sulfate and atleast one pharmaceutically acceptable excipient in a suitable solvent simultaneously or by dissolving components in a suitable solvent separately to form individual solutions and combining those solutions later.
In an embodiment, a solution of Larotrectinib sulfate and the excipient may be prepared at any suitable temperatures, such as about 0°C to about the reflux temperature of the solvent used. Stirring and heating may be used to reduce the time required for the dissolution process.
In an embodiment, a solution of Larotrectinib sulfate and the excipient may be filtered to make it clear, free of unwanted particles. In embodiments, the obtained solution may be optionally treated with an adsorbent material, such as carbon and/or hydrose, to remove colored components, etc., before filtration.
In an embodiment, removal of solvent at step b) may be carried out by methods known in the art or any procedure disclosed in the present application. In preferred embodiments, removal of solvent may include, but not limited to: solvent evaporation under atmospheric pressure or reduced pressure / vacuum such as a rotational distillation using Büchi® Rotavapor®, spray drying, freeze drying, agitated thin film drying and the like.
In preferred embodiment, the solvent may be removed under reduced pressures, at temperatures of less than about 100°C, less than about 60°C, less than about 40°C, or any other suitable temperatures.
In an embodiment, the isolation of an amorphous solid dispersion of Larotrectinib sulfate and excipient at step c) involves recovering the solid obtained in step b). The solid obtained from step b) may be recovered using techniques such as by scraping, or by shaking the container, or adding solvent to make slurry followed by filtration, or other techniques specific to the equipment used.
In an embodiment, the amorphous solid dispersion of Larotrectinib sulfate and excipient obtained from step b) may be optionally dried before or after isolating at step c).
Amorphous solid dispersion of Larotrectinib sulfate obtained at step c) may be optionally combined with atleast one additional pharmaceutically acceptable excipient at step d).
In an embodiment, amorphous solid dispersion of Larotrectinib sulfate may be combined with additional excipient using a technique known in art or by the procedures disclosed in the present application.
In preferred embodiment, amorphous solid dispersion of the present application may be combined with additional excipient either by physical blending of both the solid components or by suspending both the components in a suitable solvent and conditions, such that both the components remain unaffected. Blending may be carried out using techniques known in art such as rotatory cone dryer, fluidized bed dryer or the like optionally under reduced pressure / vacuum or inert atmosphere such nitrogen at suitable temperature and sufficient time to obtain uniform composition of amorphous solid dispersion of Larotrectinib sulfate with pharmaceutically acceptable excipient and atleast one additional pharmaceutically acceptable excipient.
In an embodiment, amorphous solid dispersion of the present application may be combined with additional excipient by evaporating the suspension or solution of amorphous solid dispersion of Larotrectinib sulfate and additional excipient.
In an embodiment, pharmaceutically acceptable additional excipient may be same or different from the excipient used in the preparation of amorphous solid dispersion of Larotrectinib sulfate. Additional excipient may include, but not limited to an inorganic oxide such as SiO2, TiO2, ZnO2, ZnO, Al2O3 and zeolite; a water insoluble polymer is selected from the group consisting of cross-linked polyvinyl pyrrolidinone, cross-linked cellulose acetate phthalate, cross-linked hydroxypropyl methyl cellulose acetate succinate, microcrystalline cellulose, polyethylene/polyvinyl alcohol copolymer, polyethylene/polyvinyl pyrrolidinone copolymer, cross-linked carboxymethyl cellulose, sodium starch glycolat, and cross-linked styrene divinyl benzene or any other excipient at any aspect of present application.
In preferred embodiment, pharmaceutically acceptable additional excipient may be selected from the group consisting of silicon dioxide, e.g. colloidal or fumed silicon dioxide or porous silica or Syloid; copolymers, such as polyethylene/polyvinyl alcohol copolymer, polyethylene/polyvinyl pyrrolidinone copolymer; and cellulose, preferably microcrystalline cellulose.
Amorphous solid dispersion of Larotrectinib sulfate isolated at step c) or d) may be dried in a suitable drying equipment such as tray dryer, vacuum oven, rotatory cone dryer, air oven, fluidized bed dryer, spin flash dryer, flash dryer, or the like. The drying may be carried out at atmospheric pressure or under reduced pressures at temperatures of less than about 100°C, less than about 60°C, less than about 40°C, or any other suitable temperatures. The drying may be carried out for any time period required for obtaining a desired quality, such as from about 15 minutes to 10 hours or longer.
In an aspect, the present application provides pharmaceutical composition comprising amorphous solid dispersion of Larotrectinib sulfate with atleast one pharmaceutically acceptable excipient and atleast one additional pharmaceutically acceptable excipient.
In an aspect, the present application provides pharmaceutical compositions comprising amorphous Larotrectinib sulfate and atleast one pharmaceutically acceptable excipient, in particular in the form of solid dispersions and adsorbates, and a process for preparing the same. In embodiments, the pharmaceutically acceptable excipient is selected from the excipients at any aspect of present application.
In embodiments, the present application provides adsorbates, wherein Larotrectinib sulfate is associated with a suitable substrate. Suitable substrate may be a particulate and/or porous substrate, wherein this substrate has an outer and/or inner surface onto which the API may be adsorbed. This means that if the substrate has pores, these pores are filled by the Larotrectinib sulfate and the substrate remains unaffected, it does not, at least not essentially, change during and / or after the adsorption. In embodiments, the suitable substrate is selected from the excipients at any aspect of present application.
Amorphous solid dispersion of Larotrectinib sulfate may be obtained alternatively either by employing a melt-extrusion technique or by combining a solution of Larotrectinib sulfate as obtained any of the aspects of present application with a suitable anti-solvent.
In another aspect, the present application provides a process for the preparation of amorphous solid dispersion of Larotrectinib sulfate together with atleast one pharmaceutically acceptable excipient, comprising the steps of:
a) providing a solution of Larotrectinib sulfate and atleast one pharmaceutically acceptable excipient in a solvent selected from the group consisting of methanol, dichloromethane and mixture thereof.
b) removing the solvent from the solution of step a);
c) isolating the amorphous solid dispersion of Larotrectinib sulfate;
d) optionally, combining amorphous solid dispersion of step c) with an additional pharmaceutically acceptable excipient.
In embodiments of this aspect, the pharmaceutically acceptable excipient is selected from the group consisting of Povidone, co-povidone, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hyroxypropylmthyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate and hydroxyethyl cellulose.
In embodiments, the steps a) to d) of this aspect may be carried out in accordance with the procedures described in any aspect of the instant applications.

In another aspect, the present application provides amorphous solid dispersion of Larotrectinib sulfate or its pharmaceutical composition comprising Larotrectinib sulfate having a chemical purity of atleast 99% by HPLC or atleast 99.5% by HPLC or atleast 99.9% by HPLC.
Certain specific aspects and embodiments of the present application will be explained in greater detail with reference to the following examples, which are provided only for purposes of illustration and should not be construed as limiting the scope of the application in any manner. Variations of the described procedures, as will be apparent to those skilled in the art, are intended to be within the scope of the present application.
Definitions
The term "about" when used in the present application preceding a number and referring to it, is meant to designate any value which lies within the range of ±10%, preferably within a range of ±5%, more preferably within a range of ±2%, still more preferably within a range of ±1 % of its value. For example "about 10" should be construed as meaning within the range of 9 to 11 , preferably within the range of 9.5 to 10.5, more preferably within the range of 9.8 to 10.2, and still more preferably within the range of 9.9 to 10.1.
The term “solvent” when used in the present application is a solvent that does not react with the reactants or reagent s under conditions that cause the chemical reaction indicated to take place.
The terms “amorphous solid dispersion of Larotrectinib sulfate” indicate that the Larotrectinib sulfate is present in substantially amorphous state in the composition (e.g. solid dispersion, adsorbate or pharmaceutical composition). "Substantially" amorphous denotes that 90 %, preferably 95 % or 99 %, more preferably all of the Larotrectinib sulfate being present in the solid dispersion, on the adsorbate or in the pharmaceutical composition is amorphous. In other words, an "amorphous" Larotrectinib sulfate composition denotes a Larotrectinib sulfate thereof-containing composition, which does not contain substantial amounts, preferably does not contain noticeable amounts, of crystalline portions of Larotrectinib sulfate thereof e.g. measurable upon X-ray powder diffraction analysis.
The term "solid dispersion" when used in the present application, denotes a state where most of the Larotrectinib sulfate, preferably 90%, 95% or all of the Larotrectinib sulfate of the solid dispersion, is homogeneously molecularly dispersed in a solid polymer matrix. Preferably solid dispersion, relates to a molecular dispersion where the API (active pharmaceutical ingredient) and polymer molecules are uniformly but irregularly dispersed in a non-ordered way. In other words, in a solid dispersion, the two components (polymer and API) form a homogeneous one-phase system, where the particle size of the API in the solid dispersion is reduced to its molecular size. In a preferred embodiment, in the solid dispersion according to the present invention no chemical bonds can be detected between the API and the polymer. In order to arrive at such a solid dispersion, preferably solid solution, it is required to have a substantial amount of API dissolved in a suitable solvent at least at one time point during preparation of said solid dispersion.
The term "adsorbate" when used in the present application, specifies that the Larotrectinib sulfateor a salt thereof is, preferably evenly, and preferably homogeneously, distributed on the inner and/or outer surface of the particulate substrate.

EXAMPLES

Example-1: Preparation of Amorphous solid dispersion of Larotrectinib sulfate with HPMC-AS(1:1 w/w).
A mixture of Larotrectinib sulfate (0.5 g) and HPMC-AS (0.5 g) was dissolved in methanol (20 mL) and stirred at 35°C. Filtered the solution to make it particle free. The solvent was evaporated in rotavapour under reduced pressure at 35°C to obtain title compound. XRPD: Amorphous(Fig.1).

Example-2: Preparation of Amorphous solid dispersion of Larotrectinib sulfate with HPMC-Pthalate(1:1 w/w).
A mixture of Larotrectinib sulfate (0.5 g) and HPMC-Pthalate (0.5 g) was dissolved in a mixture of methanol:dichloromethane (15:15 mL) at 35°C and filtered the solution to make it particle free. The solvent was evaporated in rotavapour under reduced pressure at 35°C to obtain title compound. XRPD: Amorphous(Fig.2).

Example-3: Preparation of Amorphous solid dispersion of Larotrectinib sulfate with HPMC(1:1 w/w).
A mixture of Larotrectinib sulfate (0.5 g) and HPMC (0.5 g) was dissolved in methanol (20 mL) at 35°C and filtered the solution to make it particle free. The solvent was evaporated in rotavapour under reduced pressure at 35°C to obtain title compound. XRPD: Amorphous(Fig.3).

Example-4: Preparation of Amorphous solid dispersion of Larotrectinib sulfate with HPC(1:1w/w).
A mixture of Larotrectinib sulfate (0.5 g) and HPC (0.5 g) was dissolved in methanol (20 mL) at 35°C and filtered the solution to make it particle free. The solvent was evaporated in rotavapour under reduced pressure at 35°C to obtain title compound. XRPD: Amorphous(Fig.4).

Example-5: Preparation of Amorphous solid dispersion of Larotrectinib sulfate with Povidone (PVP K-30) (1:1 w/w).
A mixture of Larotrectinib sulfate (0.5 g) and Povidone (PVP K-30) (0.5 g) was dissolved in methanol (25 mL) at 40°C and filtered the solution to make it particle free. The solvent was evaporated in rotavapour under reduced pressure at 40°C to obtain title compound. XRPD: Amorphous(Fig.5).

Example-6: Preparation of Amorphous solid dispersion of Larotrectinib sulfate with Copovidone(1:2 w/w).
A mixture of Larotrectinib sulfate (0.5 g) and Copovidone (1.0 g) was dissolved in methanol (20 mL) at 35°C and filtered the solution to make it particle free. The solvent was evaporated in rotavapour under reduced pressure at 40°C to obtain title compound. XRPD: Amorphous(Fig.6).
,CLAIMS:Claims:
1. A process for the preparation of amorphous solid dispersion of Larotrectinib sulfate together with atleast one pharmaceutically acceptable excipient, comprising the steps of:
a. providing a solution of Larotrectinib sulfate and atleast one pharmaceutically acceptable excipient in a suitable solvent;
b. removing the solvent from the solution of step a);
c. isolating the amorphous solid dispersion of Larotrectinib sulfate;
d. optionally, combining amorphous solid dispersion of step c) with an additional pharmaceutically acceptable excipient.

2. An amorphous solid dispersion of Larotrectinib sulfate together with atleast one pharmaceutically acceptable excipient.

3. The pharmaceutically acceptable excipient of claims 1 and 2, is selected from the group consisting of polyvinyl pyrrolidone (povidone) K-30, Povidone K-60, Povidone K-90, polyvinylpyrrolidone vinylacetate, co-povidone NF, polyvinylacetal diethylaminoacetate (AEA®), polyvinyl acetate phthalate, polysorbate 80, polyoxyethylene–polyoxypropylene copolymers (Poloxamer® 188), polyoxyethylene (40) stearate, polyethyene glycol monomethyl ether, polyethyene glycol, poloxamer 188, pluronic F-68, methylcellulose, methacrylic acid copolymer (Eudragit or Eudragit-RLPO), hydroxypropylmethyl cellulose phthalate (HPMC-phthalate, hydroxypropylmethyl cellulose (HPMC), hydroxypropylmethyl cellulose acetate succinate (HPMC-AS), hydroxypropyl cellulose SSL(HPC-SSL), hydroxypropyl cellulose SL(HPC-SL), hydroxypropyl cellulose (HPC), hydroxypropyl cellulose L (HPC-L), hydroxyethyl cellulose, Soluplus® (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (PCL-PVAc-PEG)), gelucire 44/14, ethyl cellulose, D-alpha-tocopheryl polyethylene glycol 1000 succinate, cellulose acetate phthalate, and carboxymethylethylcellulose.

4. The pharmaceutically acceptable excipient of claims 1 and 2, is selected from the group consisting of Povidone, co-povidone, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hyroxypropylmthyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate and hydroxyethyl cellulose.

5. The process of claim 2, wherein the removal of solvent at step b) is carried out by evaporating the solvent under atmospheric pressure or reduced pressure.

6. The process of claim 2, wherein the solvent of step a) is selected from the group consisting of methanol, ethanol, 2-propanol, 1-butanol, 2-butanol, acetone, methyl ethyl ketone, methyl isobutyl ketone, methyl acetate, ethyl acetate, isopropyl acetate, dichloromethane, tetrahydrofuran, water and mixtures thereof.

7. A process for the preparation of amorphous solid dispersion of Larotrectinib sulfate together with atleast one pharmaceutically acceptable excipient, comprising the steps of:
a. providing a solution of Larotrectinib sulfate and atleast one pharmaceutically acceptable excipient in a solvent selected from the group consisting of methanol, dichloromethane and mixture thereof.
b. removing the solvent from the solution of step a);
c. isolating the amorphous solid dispersion of Larotrectinib sulfate;
d. optionally, combining amorphous solid dispersion of step c) with an additional pharmaceutically acceptable excipient.

8. The process of claim 7, wherein the pharmaceutically acceptable excipient is selected from the group consisting of Povidone, co-povidone, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hyroxypropylmthyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate and hydroxyethyl cellulose.

9. A pharmaceutical composition comprising the amorphous solid dispersion of Larotrectinib sulfate of claim 1.